'Golden era of innovation': ORI Capital raises $260M fund for early-stage biotechs gmasson Thu, 02/22/2024 - 10:20.: ORI Capital has raised $260 million, the venture capital firm’s second life sciences fund that will go toward early-stage biotechs worldwide. The Hong Kong- and U.S.-based investment firm will support companies focused on diagnostics, therapeutics and drug delivery for conditions with large unmet need and high mortality rates, according to a Feb. 22 release. Those indications include cancer, metabolic disorders and neurodegenerative diseases, ORI said.